Posted by Michael Wonder on 20 Oct 2022
US FDA grants emergency use authorisation for Novavax COVID-19 Vaccine, adjuvanted as a booster for adults
19 October 2022 - Novavax today announced that the Novavax COVID-19 Vaccine, Adjuvanted (NVX-CoV2373) has received emergency use authorisation from the US FDA.
The approval is to provide a first booster dose at least six months after completion of primary vaccination with an authorised or approved COVID-19 vaccine to individuals 18 years of age and older for whom an FDA authorised mRNA bivalent COVID-19 booster vaccine is not accessible or clinically appropriate, and to individuals 18 years of age and older who elect to receive the Novavax COVID-19 Vaccine, Adjuvanted because they would otherwise not receive a booster dose of a COVID-19 vaccine.
